Collectively, these results suggest that the macrophage IL-10–STAT3 pathway could be a good target for therapies to block macrophage-promoted cyst expansion and thus to slow ADPKD disease progression. This evidence concerns the gene IL10 and autosomal dominant polycystic kidney disease.